Could a single daily pill replace complex HIV regimens?

NCT ID NCT00196612

Completed Disease control Sponsor: ANRS, Emerging Infectious Diseases Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This trial compares a once-daily combination of three HIV drugs (emtricitabine, didanosine, and efavirenz) to the standard multi-pill regimen containing a protease inhibitor. The goal is to see if the simpler daily pill works just as well at keeping the virus undetectable, while causing fewer side effects and being easier for patients to take. The study includes adults with HIV who have had an undetectable viral load for at least six months on their current therapy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: emtricitabine, didanosine, efavirenz
What this could lead to: If successful, this could offer people with HIV a simpler, once-daily treatment option with fewer side effects and better quality of life.
What could go wrong: This is a phase 3 trial, so results are not yet confirmed. The once-daily combo may prove less effective or cause unexpected side effects in some people.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV INFECTIONS

Contacts and locations

Locations

Service de Maladies Infectieuses, Hôpital Saint-Louis

Paris, 75475, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.